Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms

Archives of General Psychiatry

Volumn 51, Issue 11, 1994, Pages 898-911

  Krystal, John H ^a   Webb, Elizabeth ^a   Cooney, Ned ^a   Kranzler, Henry R ^a,b   Charney, Dennis S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROCORTISONE; MECOPROP; PROLACTIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; YOHIMBINE;

ADULT; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORADRENERGIC SYSTEM; PROLACTIN BLOOD LEVEL;

ADULT; AFFECT; ALCOHOL DRINKING; ALCOHOLISM; ANXIETY; BLOOD PRESSURE; COCAINE; ETHANOL; HOSPITALIZATION; HUMAN; HYDROCORTISONE; MALE; MARIJUANA ABUSE; MIDDLE AGE; PIPERAZINES; PLACEBOS; PROLACTIN; RECEPTORS, ADRENERGIC; RECEPTORS, SEROTONIN; SUBSTANCE-RELATED DISORDERS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; YOHIMBINE;

EID: 0028006609     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1994.03950110058008     Document Type: Article

References (103)

1. Signs SA, Schechter MD. The role of dopamine and serotonin receptors in the mediation of the ethanol interoceptive cue. Pharmacol Biochem Behav. 1988;30: 55–64.
2. Grant KA, Colombo G, Gatto GJ. Characterization of 5-HT, receptor agonists and the mediation of ethanolmimetic discriminative stimulus effects. Alcohoi Clin Exp Res. 1993;17:334.
3. Benkelfat C, Murphy DL, Hill JL, George DT, Nutt D, Linnoila M. Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry. 1991;48:383.
4. Lee MA, Meltzer HY. Neuroendocrine responses to serotonergic agents in alcoholics. Biol Psychiatry. 1991;30: 1017–1030.
5. Moss HB, Yao JK, Panzak GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry. 1990;28: 325–328.
6. Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety, II: effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology. 1987;92: 14–24.
7. Zacchia C, Pihl RO, Young S, Ervin F. The influence of altered tryptophan availability on ethanol intoxication in normal men. J Stud Alcohol. 1987;48: 535–540.
8. Corrodi H, Fuxe K, Hockfelt T. The effect of ethanol on the activity of the catecholamine neurons in the rat brain. J Pharm Pharmacol. 1966;18: 821–823.
9. Poherecky LA, Jaffe LS. Noradrenergic involvement in the acute effects of ethanol. Res Commun Chem Pathol Pharmacol. 1975;12: 433–447.
10. Karoum F, Wyatt RJ, Majchrowicz E. Brain concentrations of biogenic-amine metabolites in acutely treated and ethanol dependent rats. Br J Pharmacol. 1976;56: 403–411.
11. Amit Z, Brown ZW. Actions of drugs of abuse on brain reward systems: a reconsideration with specific attention to alcohol. Pharmacol Biochem Behav. 1982;17: 233–238.
12. Verbanck P, Seutin V, Massotte L, Dresse A. Yohimbine can induce ethanol tolerance in an in vitro preparation of rat locus coeruleus. Alcohol Clin Exp Res. 1991;15: 1036–1039.
13. Shiirao I, Tsuda A, Ida Y, Tsujimaru S, Satoh H, Oguchi M, Tanaka M, Inanaga K. Effect of acute ethanol administration on noradrenaline metabolism in brain regions in stressed and non-stressed rats. Pharmacol Biochem Behav. 1988;30: 769–773.
14. Durcan MJ, Lister RG, Linnoila M. Behavioral effects of alpha 2 adrenoceptor antagonists and their interactions with ethanol in tests of locomotion, exploration and anxiety in mice. Psychopharmacology. 1989;97: 189–193.
15. Lister RG, Durcan MJ, Nutt DJ, Linnoila M. Attenuation of ethanol intoxication by alpha adrenoceptor antagonists. Life Sci. 1989;44: 111–119.
16. Borg S, Kvande H, Sedvall G. Central norepinephrine metabolism during alcohol intoxication in addicts and healthy volunteers. Science. 1981;213: 1135–1137.
17. McDougle CJ, Krystal JH, Price LH, Heninger GR, Charney DS. Noradrenergic response to acute ethanol administration in healthy human subjects: comparison with intravenous yohimbine. Psychopharmacology. In press.
18. Ahlenius S, Carlsson A, Engel J, Svensson T, Sodersten P. Antagonism by alpha methyltyrosine of the ethanol-induced stimulation and euphoria in man. Clin Pharmacol Ther. 1973;14: 586–591.
19. Perez-Reyes M, White WR, McDonald SA, Hicks RE. Interaction between ethanol and dextroamphetamine: effects on psychomotor performance. Alcohol Clin Exp Res. 1992;16: 75–81.
20. Murphy JM, McBride WJ, Lumeng L, Li T-K. Contents of monoamines in forebrain regions of alcohol-preferring (P) and -nonpreferring (NP) lines of rats. Pharmacol Biochem Behav. 1987;26: 389–392.
21. Wong DT, Threlkeld PG, Lumeng L, Li T-K. Higher density of serotonin-1A receptors in the hippocampus and cerebral cortex of alcohol-preferring P rats. Life Sci. 1990;46: 231–235.
22. Korpi ER, Paivarinta P, Abi-Dargham A, Honkanen A, Laruelle M, Tuominen K, Hiilakivi LA. Binding of serotonergic ligands to brain membranes of alcoholpreferring AA and alcohol-avoiding ANA rats. Alcohol. 1992;9: 369–374.
23. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci. 1992;13: 69–75.
24. Holman RB, Hoyland V, Shillito EE. The failure of p-chlorophenylalanine to affect voluntary alcohol consumption in rats. Br J Pharmacol. 1975;53: 299–304.
25. Pihl RO, Young SN, Ervin FR, Plotnick S. Influence of tryptophan availability on selection of alcohol and water by men. J Stud Alcohol. 1987;48: 260–264.
26. Coccaro EF, Soever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989;46: 587–599.
27. Friedman MJ, Krstulovic AM, Severinghaus JM, Brown SJ. Altered conversion of tryptophan to kynurenine in newly abstinent alcoholics. Biol Psychiatry. 1988;23: 89–93.
28. Olsen RE, Gursey D, Vester J. Evidence for a defect in tryptophan metabolism in chronic alcoholism. N Engl J Med. 1960;263: 1169–1174.
29. Ballenger JC, Goodwin FK, Major LF, Brown GL. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry. 1979;36: 224–227.
30. Thomson SM Jr, McMillen BA. Test for decreased serotonin/tryptophan metabolite ratios in abstinent alcoholics. Alcohol. 1987;4: 1–5.
31. Naranjo CA, Sellers EM, Lawrin MO. Modulation of ethanol intake by serotonin uptake inhibitors. J Clin Psychiatry. 1986;47(suppl 4): 16–22.
32. Kranzler HR, Meyer RE. An open trial of buspirone in alcoholics. J Clin Psychopharmacol. 1989;9: 379–380.
33. Wong DR, Lumeng L, Threlkeld PG, Reid LR, Li T-K. Serotonergic and adrenergic receptors in alcohol-preferring and non-preferring rats. J Neural Transm. 1988;71: 207–218.
34. Kiianmaa K, Fuxe K, Jonsson G, Ahtee L. Evidence for involvement of central NA neurons in alcohol intake: increased alcohol consumption after degeneration of the NA pathway to the cortex cerebri. Neurosci Lett. 1975;1: 41–45.
35. Mason ST, Corcoran ME, Fibiger HC. Noradrenaline and ethanol intake in the rat. Neurosci Lett. 1979;12: 137–142.
36. Hubbell CL, Delconte JD, Amendola CA, Nichols ML, Reid LD. Adrenergic drugs and rats' intake of alcoholic beverage. Soc Neurosci Abstracts. 1991;16:1422.
37. Opitz K. The effect of clonidine and related substances on voluntary ethanol consumption in rats. Drug Alcohol Depend. 1990;25: 43–48.
38. Meyer RE. Prospects for a rational pharmacotherapy of alcoholism. J Clin Psychiatry. 1989;50: 403–412.
39. Bjorkquist SE. Clonidine in alcohol withdrawal. Acta Psychol Scand. 1975;52: 256–263.
40. Baumgartner GR, Rowen RC. Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Arch Intern Med. 1987;147: 1223–1226.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
42. Spitzer RI, Williams JBW, Gibbgon M, First MB. The Structured Clinical Interview for DSM-lll-R, I: history, rationale, and description. Arch Gen Psychiatry. 1992;49: 624–629.
43. Gough HG, ed. CPI Administrator's Guide. Palo Alto, Calif: Consulting Psychologists Inventory Press Inc; 1987.
44. Cooney NL, Kadden RM, Litt MD. A comparison of methods for assessing sociopathy in male and female alcoholics. J Stud Alcohol. 1990;51: 42–48.
45. Selzer ML. The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry. 1971;127: 1653–1658.
46. von Knorring AL, Bohman M, von Knorring L, Oreland L. Platelet MAO activity as a biological marker in subgroups of alcoholism. Acta Psychiatr Scand. 1985;72: 51–58.
47. Lamparski DM, Roy A, Nutt DJ, Linnoila M. The criteria of Cloninger et al and von Knorring et al for subgrouping alcoholics: a comparison in a clinical population. Acta Psychiatr Scand. 1991;84: 497–502.
48. Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolau A, Heninger GR, Charney DS. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 1993;50: 266–274.
49. Southwick SM, Krystal JH, Morgan A, Nagy LM, Dan E, Johnson D, Bremner D, Charney DS. Yohimbine and m-chlorophenylpiperzine in PTSD. In: 1991 New Research Program and Abstracts, American Psychiatric Association, 144th Annual Meeting; May 11–16, 1991; New Orleans, La. Abstract NR348.
50. Keane TM, Caddell JM, Taylor KL. Mississippi scale for combat-related posttraumatic stress disorder: three studies in reliability and validity. J Consult Clin Psychol. 1988;56: 85–90.
51. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand. 1992;86: 273–282.
52. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988;45: 177–185.
53. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients: evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry. 1993;50: 624–635.
54. Krystal JH, McDougle CJ, Woods SW, Price LH, Heninger GR, Charney DS. Dose response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology. 1992;108: 313–319.
55. Maisto SA, Conners GJ, Tucker JA, McCollam JB, Addesso VJ. Validation of the sensation scale: a measure of subjective physiological responses to alcohol. Behav Res Ther. 1980;18: 37–43.
56. Tiffany ST, Drobes DJ. Development and validation of a questionnaire on smoking urges. Br J Addict. 1991;86: 1467–1476.
57. Tiffany ST, Singleton E, Haertzen C, Henningfield JE. The development of a cocaine craving questionnaire. Drug Alcohol Depend. In press.
58. Maas JW, Hattox SE, Landis DH, Roth RH. The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenylethylene glycol (MHPG). Brain Res. 1976;118: 167–173.
59. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York, NY: McGraw-Hill International Book Co; 1971.
60. American Psychiatric Association Commission on Psychotherapies. Psychotherapy Research: Methodological and Efficacy Issues. Washington, DC: American Psychiatric Press; 1982.
61. Wolf WA, Kuhn DM. The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP. Neurochem Int. 1991;19: 39–44.
62. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res. 1988;8: 59–81.
63. Hamik A, Peroutka SJ. 1-(m-chlorophenyl)piperazine interactions with neurotransmitter receptors in the human brain. Biol Psychiatry. 1989;25: 569–575.
64. Glennon RA, Lsmaiel AE-KM, McCarthy BG, Peroutka SJ. Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. Eur J Pharmacol. 1989;168: 387–392.
65. Schoeffter P, Hoyer D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1c and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Arch Pharmacol. 1989;339: 675–683.
66. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 receptor subtype. J Biol Chem. 1993;268: 18200–18204.
67. Sheldon PW, Aghajanian GK. Excitatory responses to serotonin (5-HT) in neurons of the rat piriform cortex: evidence for mediation by 5-HT1C receptors in pyramidal cells and 5-HT2 receptors in interneurons. Synapse. 1991;9: 208–218.
68. Conn PJ, Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C) receptors. J Pharmacol Exp Ther. 1987;2142: 552–557.
69. Sheldon PW, Aghajanian GK. Serotonin (5-HT) induces IPSP's in pyramidal layer cells of rat piriform cortex: evidence for the involvement of a 5-HT2 activated interneuron. Brain Res. 1990;506: 62–69.
70. Carver JG, Grahame-Smith DG, Johnson ES, Madgwick Z. The effects of 5-HT and m-chlorophenylpiperazine (m-CPP) on the efflux of [3H]-5-HT from human perfused platelets. Br J Clin Pharmacology. 1993;35: 473–478.
71. Ireland SJ, Tyers MB. Pharmacological characterization of 5-hydroxytryptamineinduced depolarization of the rabbit isolated vagus nerve. Br J Pharmacol. 1987;90:229.
72. Robertson DW, Bloomquist W, Wong DT, Cohen ML. MCPP but not TFMPP is an antagonist at cardiac 5-HT3 receptors. Life Sci. 1992;50: 599–605.
73. Benloucif S, Galloway MP. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol. 1991;200: 1–8.
74. Siever LJ, Kahn RS, Lawlor BA, Trestman RL, Lawrence TL, Coccaro EF. Critical issues in defining the role of serotonin in psychiatric disorders. Pharmacol Rev. 1991;43: 509–525.
75. Murphy DL, Lesch KP, Aulakh CS, Pigott TA. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev. 1991;43: 528–552.
76. Krystal JH, Webb E, Kranzler H, Cooney N, Heninger GR, Charney DS. Yohimbine and MCPP effects in alcoholics and healthy subjects. Alcohol Clin Exp Res. 1992;16:234.
77. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 1988;85: 5274–5278.
78. Pomerleau OF, Fertig J, Baker L, Cooney N. Reactivity to alcohol cues in alcoholics and non-alcoholics: implications for a stimulus control analysis of drinking. Addict Behav. 1983;8: 1–10.
79. Rohsenow DJ, Niaura RS, Childress AR, Abrams DB, Monti PM. Cue reactivity in addictive behaviors: theoretical and treatment implications. Int J Addict. 1991;25: 957–993.
80. Engle KB, Williams TK. Effect of an ounce of vodka on alcoholics desire for alcohol. QJ Stud Alcohol. 1972;33: 1099–1105.
81. Ludwig AM, Wikler A, Stark L. The first drink: psychobiological aspects of craving. Arch Gen Psychiatry. 1974;30: 539–547.
82. Hodgson R, Rankin H, Stockwell T. Alcohol dependence and the priming effect. Behav Res Ther. 1979;17: 379–387.
83. Childress AR, Ehrman R, McLellan AT, Natale M, O'Brien CP. Mood states can elicit drug craving and conditioned withdrawal in opiate abuse patients. NIDA Res Monogr. 1986;76: 137–144.
84. Litt MD, Cooney NL, Kadden RM, Gaupp L. Reactivity to alcohol cues and induced moods in alcoholics. Addict Behav. 1990;15: 137–146.
85. Buydens-Branchey L, Branchey MH, Noumair D, Lieber CS. Age of alcoholism onset, II: relationship to susceptibility to serotonin precursor availability. Arch Gen Psychiatry. 1989;46: 231–236.
86. Roy A, Virkkunen M, Linnoila M. Reduced central serotonin turnover in a subgroup of alcoholics? Prog Neuropsychopharmacol Biol Psychiatry. 1987;11: 173–177.
87. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. Science. 1987;236: 410–416.
88. Germaine M, Goddard AW, Woods SW, Charney DS, Heninger GR. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry. 1992;32: 457–461.
89. Wetzler S, Kahn RS, Asnis GM, Korn M, van Praag HM. Serotonin receptor sensitivity and aggression. Psychiatry Res. 1991;37: 271–279.
90. Holmberg G, Gershon S. Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia (Berl). 1961;2: 93–106.
91. Ingram CG. Some pharmacologic actions of yohimbine and chlorpromazine in man. Clin Pharmacol Ther. 1962;3: 345–352.
92. Charney DS, Heninger GR, Sternberg DE. Assessment of α2 autoreceptor function in humans: effects of oral yohimbine. Life Sci. 1982;30: 2033–2041.
93. Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR. Noradrenergic dysregulation in panic disorder. In: Ballenger JC, ed. Neurobiology of Panic Disorder. New York, NY: Alan R Liss Inc; 1990: 91–105.
94. Redmond DE Jr. New and old evidence for the involvement of a brain norepinephrine system in anxiety. In: Fann WE, ed. The Phenomenology and Treatment of Anxiety. New York, NY: Plenum Publishing Corp; 1979: 153–203.
95. Goldberg MR, Robinson D. Yohimbine: a pharmacological probe for study of the α2 adrenoreceptor. Pharmacol Rev. 1983;35: 143–180.
96. van Oene JC, de Vries JB, Horn AS. The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1984;327: 304–311.
97. Peroutka SJ, Switzer JA, Hamik A. Identification of 5-hydroxytryptamine1D binding sites in human brain membranes. Synapse. 1989;3: 61–66.
98. Petrakis I, Webb E, Abi-Dargham A, Cooney N, Charney DS, Krystal JH. Serotonin contributions to cue-induced craving in alcoholics. Alcohol Clin Exp Res. 1993;17:335.
99. Schuster CR, Balster RL. The discriminative stimulus properties of drugs. Adv Behav Pharmacol. 1977;1: 85–138.
100. Seibyl JP, Krystal JH, Price LH, Woods SW, D'Amico C, Heninger GR, Charney DS. Effects of ritanserin on the behavioral, neuroendocrine and cardiovascular responses to m-chlorophenylpiperazine in healthy human subjects. Psychiatry Res. 1991;38: 227–236.
101. Krystal JH, Seibyl JP, Karper L, Erdos J, Wong ML, Heninger GR, Charney DS. Clozapine versus haloperidol blockade of M-CPP in schizophrenia. In: 1992 New Research Program and Abstracts, American Psychiatric Association, 145th Annual Meeting; May 2–7, 1992; Washington, DC. Abstract NR428.
102. Krystal JH, Seibyl JP, Karper L, Wong ML, Erdos J, Heninger GR, Charney DS. Ritanserin blockade of M-CPP effects in schizophrenia. In: 1992 New Research Program and Abstracts, American Psychiatric Association, 145th Annual Meeting; May 2–7, 1992; Washington, DC. Abstract NR429.
103. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B. Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992;49: 599–608.